Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03467542 · ClinicalTrials.gov registry record · NA
PHIL in the Treatment of Intracranial dAVF.
A NA study of Arteriovenous Dural Fistula, sponsored by Microvention-Terumo.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT03467542 is a NA study of Arteriovenous Dural Fistula that has completed, run by Microvention-Terumo. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03467542, a NA study of Arteriovenous Dural Fistula, has completed, sponsored by Microvention-Terumo.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
Conditions Studied
Interventions
- DEVICE PHIL® Liquid Embolic System
Study Locations (1)
New York
- Albany Medical Center - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-08-24 |
| Est. Completion | 2022-12-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03467542
The ClinicalTrials.gov registry entry for NCT03467542 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Microvention-Terumo, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arteriovenous Dural Fistula appearing as the primary indexed condition, and to 1 intervention - of which PHIL® Liquid Embolic System is the first listed.
NCT03467542 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03467542 about?
NCT03467542 is a clinical study titled "PHIL in the Treatment of Intracranial dAVF.". This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
What is the current status of trial NCT03467542?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2018-08-24. Estimated completion is 2022-12-12.
What conditions does trial NCT03467542 study?
This clinical trial studies the following conditions: Arteriovenous Dural Fistula.
What interventions are being tested in trial NCT03467542?
The interventions under investigation include: PHIL® Liquid Embolic System (DEVICE).
Who is sponsoring clinical trial NCT03467542?
This trial is sponsored by Microvention-Terumo, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03467542 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.